




Searching News Database: protein degradation
HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
HSMN NewsFeed - 20 Jan 2022
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
HSMN NewsFeed - 20 Nov 2019
Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
HSMN NewsFeed - 30 Apr 2019
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
HSMN NewsFeed - 4 Apr 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
HSMN NewsFeed - 9 Apr 2013
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
HSMN NewsFeed - 25 Feb 2009
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Additional items found! 2

Members Archive contains
2 additional stories matching:
protein degradation
(Password required)
protein degradation
(Password required)